- Patent Title: Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
-
Application No.: US14895613Application Date: 2014-06-09
-
Publication No.: US09951079B2Publication Date: 2018-04-24
- Inventor: Mark W. Embrey , Kerim Babaoglu , Abbas Walji , John S. Wai , Paul J. Coleman
- Applicant: MERCK SHARP & DOHME CORP.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Nicole M. Beeler; John C. Todaro
- International Application: PCT/US2014/041464 WO 20140609
- International Announcement: WO2014/200880 WO 20141218
- Main IPC: C07D487/14
- IPC: C07D487/14 ; C07D498/14 ; C07D491/048 ; A61K31/5383 ; A61K31/4965 ; A61K45/06 ; A61K31/4985
Abstract:
The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, m, R1, R5, Ra and Rb are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.
Public/Granted literature
- US20170305923A1 FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS Public/Granted day:2017-10-26
Information query
